The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

Market Overview

• Current Market Size: Grew from $8.09 billion in 2023 to $8.96 billion in 2024.
• Growth Rate: Compound annual growth rate (CAGR) of 10.7%.
• Historic Growth Drivers:
  • Increased investment in drug discovery.
  • Growth in research and development activities.
  • Presence of healthcare research centers and academic institutions.

Future Market Projections

• Expected Market Size: Projected to reach $13.21 billion by 2028.
• Future Growth Rate: CAGR of 10.2%.
• Future Growth Drivers:
  • Rising demand for antibody drug discovery services and platforms.
  • Increased funding for novel technology development.
  • Growing demand for precision therapeutics.
  • Broader use of antibodies beyond conventional therapeutic roles.

View More On The Antibody Discovery Market Report 2024 – https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

Key Market Trends

• R&D Activities: Surge in research and development.
• Monoclonal Antibodies: Growing demand for monoclonal antibodies.
• Advanced Technologies: Increased adoption of advanced technologies.
• Targeted Therapeutics: Rising demand for targeted therapeutics.
• Novel Antibody Formats: Development of new antibody formats.

Precision Therapeutics: Driving Market Growth

• Customization: Tailored medical treatments for individual patient characteristics.
• Targeted Therapies: Development of monoclonal antibodies for specific disease-related molecules or cells.
• FDA Approvals: In 2022, 34% of new molecular entities were classified as personalized medicines by the Personalized Medicine Coalition.
• Impact: The growing need for precision therapeutics is a significant market driver.

Major Players in the Market

• Companies: Danaher Corporation, Eurofins Scientific, Sartorius AG, Charles River Laboratories, Bruker Corporation, WuXi Biologics, Genmab A/S, Evotec, Cambrex Corporation, ChemPartner, Aragen Life Science Pvt Ltd, Genscript Technology Corporation, Biocytogen, Alcami Corporation Inc, Twist Bioscience, BioDuro-Sundia.

AI-Powered Platforms Revolutionizing Therapeutic Development

• Innovative Technologies: Companies developing AI-based computational antibody drug discovery platforms.
• Efficiency and Precision: AI expedites the identification and optimization of therapeutic antibodies.
• Case Study:
  • SwiftPharma BV: Introduced an AI-driven antibody discovery platform in October 2023.
  • Technologies Used: Combines AI, big data, machine learning, and phage display.
  • Benefits: Rapid prediction of high-specificity and high-affinity antibody-antigen binding.

Strategic Acquisitions Enhancing Market Capabilities

• Twist Bioscience Acquisition of Abveris:
  • Date: November 2021.
  • Impact: Enhanced Twist’s biopharmacy antibody capabilities, particularly in mouse-based discovery and screening.
  • Abveris: A US-based antibody discovery services company.

Market Segmentation

• By Methods: Phage Display, Hybridoma, Other Methods.
• By Antibody Type: Humanized Antibody, Human Antibody, Chimeric Antibody, Murine Antibody.
• By End Users: Pharmaceutical and Biotechnology Industry, Research Laboratory, Academic Laboratory.

Regional Insights

• Largest Region: North America dominated the market in 2023.
• Fastest-Growing Region: Asia-Pacific is expected to see the fastest growth in the forecast period.

The antibody discovery market is poised for significant growth driven by advancements in precision therapeutics, innovative technologies, and strategic acquisitions. With increasing investments in R&D and a growing demand for targeted therapies, the market is set to expand rapidly in the coming years.

Request A Sample Of The Global Antibody Discovery Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=13783&type=smp